Sichuan Hebang Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sichuan Hebang Biotechnology.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Chemicals kazanç büyümesi	38.3%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Sep 25

Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Aug 16

Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Jun 04

Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

May 13

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Mar 07

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Apr 21

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Sichuan Hebang Biotechnology yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SHSE:603077 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	9,203	486	-933	-205	N/A
6/30/2024	9,582	859	-1,159	-362	N/A
3/31/2024	8,429	916	-1,572	-700	N/A
12/31/2023	8,824	1,283	-748	80	N/A
9/30/2023	8,980	1,398	272	886	N/A
6/30/2023	9,651	1,789	575	1,246	N/A
3/31/2023	12,347	3,161	1,541	2,383	N/A
12/31/2022	13,039	3,807	1,708	2,644	N/A
9/30/2022	13,353	4,438	773	2,970	N/A
6/30/2022	13,517	4,741	1,682	3,670	N/A
3/31/2022	11,409	3,815	1,535	3,537	N/A
12/31/2021	9,987	3,018	1,462	3,271	N/A
9/30/2021	8,494	2,248	1,975	2,627	N/A
6/30/2021	6,768	908	1,276	1,829	N/A
3/31/2021	5,902	319	685	843	N/A
12/31/2020	5,261	41	172	369	N/A
9/30/2020	5,115	-147	-307	79	N/A
6/30/2020	5,351	264	-572	13	N/A
3/31/2020	5,565	372	-668	11	N/A
12/31/2019	5,969	517	-500	163	N/A
9/30/2019	6,200	380	-243	378	N/A
6/30/2019	6,154	387	40	488	N/A
3/31/2019	6,285	426	537	954	N/A
12/31/2018	6,009	363	581	944	N/A
9/30/2018	5,990	622	574	967	N/A
6/30/2018	5,625	535	N/A	1,005	N/A
3/31/2018	4,961	395	N/A	378	N/A
12/31/2017	4,738	518	N/A	177	N/A
9/30/2017	4,400	477	N/A	189	N/A
6/30/2017	4,041	451	N/A	247	N/A
3/31/2017	3,722	436	N/A	270	N/A
12/31/2016	3,463	318	N/A	575	N/A
9/30/2016	3,206	260	N/A	558	N/A
6/30/2016	2,954	226	N/A	248	N/A
3/31/2016	3,043	255	N/A	548	N/A
12/31/2015	2,863	240	N/A	449	N/A
9/30/2015	2,757	144	N/A	173	N/A
6/30/2015	2,628	135	N/A	325	N/A
3/31/2015	2,282	679	N/A	-9	N/A
12/31/2014	2,186	672	N/A	205	N/A
9/30/2014	1,979	715	N/A	-20	N/A
6/30/2014	1,871	696	N/A	-172	N/A
3/31/2014	1,660	54	N/A	-121	N/A
12/31/2013	1,603	64	N/A	-407	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 603077's forecast earnings growth is above the savings rate (2.9%).

Kazançlar ve Piyasa: Insufficient data to determine if 603077's earnings are forecast to grow faster than the CN market

Yüksek Büyüme Kazançları: Insufficient data to determine if 603077's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 603077's revenue is forecast to grow faster than the CN market.

Yüksek Büyüme Geliri: Insufficient data to determine if 603077's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 603077's Return on Equity is forecast to be high in 3 years time

Sichuan Hebang Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased to CN¥6.00

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.004 (vs CN¥0.046 in 3Q 2023)

Investor sentiment improves as stock rises 25%

Sichuan Hebang Biotechnology Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Second quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.025 in 2Q 2023)

Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 200 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited to Report First Half, 2024 Results on Aug 30, 2024

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 200 million worth of its shares.

Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

Sichuan Hebang Biotechnology Corporation Limited, Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.004 (vs CN¥0.046 in 1Q 2023)

Sichuan Hebang Biotechnology Corporation Limited to Report Q1, 2024 Results on Apr 27, 2024

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.092 in 3Q 2022)

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

New minor risk - Profit margin trend

Sichuan Hebang Biotechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.12 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.36 in FY 2021)

Price target increased to CN¥6.00

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.078 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.03 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.078 (vs CN¥0.009 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.004 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.005 (vs CN¥0.06 in FY 2019)

New 90-day high: CN¥1.57

New 90-day low: CN¥1.32

New 90-day low: CN¥1.33

New 90-day high: CN¥1.52

Third quarter earnings released

New 90-day low: CN¥1.34

SichuanHebang Biotechnology Co.,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high - CN¥1.63

First half earnings released

New 90-day high - CN¥1.48

SichuanHebang Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin